en
×

分享给微信好友或者朋友圈

使用微信“扫一扫”功能。
通讯作者:

张翔,E-mail: zhangxiang1101@126.com

中图分类号:R604

文献标识码:A

DOI:10.3969/j.issn.1007-6948.2024.05.021

参考文献 1
Franck C,MÜller C,Rosania R,et al.Advanced pancreatic ductal adenocarcinoma:moving forward[J].Cancers,2020,12(7):1955.
参考文献 2
Mizrahi JD,Surana R,Valle JW,et al.Pancreatic cancer [J].Lancet,2020,395(10242):2008-2020.
参考文献 3
Gu XJ,Liu R.Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly[J].Clin Interv Aging,2016,11:1365-1370.
参考文献 4
Balthazar EJ.Pancreatitis associated with pancreatic carcinoma.Preoperative diagnosis:role of CT imaging in detection and evaluation[J].Pancreatology,2005,5(4/5):330-344.
参考文献 5
Ruan ZB,Jiao J,Min DY,et al.Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head [J].Oncol Lett,2018,15(6):9735-9744.
参考文献 6
Yadav AK,Sharma R,Kandasamy D,et al.Perfusion CT-Can it resolve the pancreatic carcinoma versus mass forming chronic pancreatitis conundrum?[J].Pancreatology,2016,16(6):979-987.
参考文献 7
Yin QH,Zou XN,Zai XD,et al.Pancreatic ductal adenocarcinoma and chronic mass-forming pancreatitis:differentiation with dual-energy MDCT in spectral imaging mode[J].Eur J Radiol,2015,84(12):2470-2476.
参考文献 8
Lu N,Feng XY,Hao SJ,et al.64-slice CT perfusion imaging of pancreatic adenocarcinoma and mass-forming chronic pancreatitis [J].Acad Radiol,2011,18(1):81-88.
参考文献 9
Ren S,Chen X,Cui WJ,et al.Differentiation of chronic massforming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography [J].Cancer Manag Res,2019,11:7857-7866.
参考文献 10
Elsherif SB,Virarkar M,Javadi S,et al.Pancreatitis and PDAC:association and differentiation[J].Abdom Radiol(NY),2020,45(5):1324-1337.
参考文献 11
Deng Y,Ming B,Zhou T,et al.Radiomics model based on MR images to discriminate pancreatic ductal adenocarcinoma and mass-forming chronic pancreatitis lesions [J].Front Oncol,2021,11:620981.
参考文献 12
陈祺,李东恩,姜建帅.195 例早期胰腺癌手术方式与生存率的关系[J].中国中西医结合外科杂志,2016,22(1):3-5.
参考文献 13
张太平,李建,赵玉沛.胰头部肿块型慢性胰腺炎的处理对策 [J].中华消化外科杂志,2014,13(4):244-246.
参考文献 14
Azizian A,RÜhlmann F,Krause T,et al.CA19-9 for detecting recurrence of pancreatic cancer[J].Sci Rep,2020,10(1):1332.
参考文献 15
Beker K,Lee KS,Tsai LL,et al.Differentiation of pancreatic head ductal adenocarcinoma from inflammatory pancreatic pseudomass by MR cholangio-pancreatography:utility of the duct-interrupted,corona,and attraction signs[J].Abdom Radiol(NY),2019,44(12):4048-4056.
参考文献 16
Galia M,Albano D,Picone D,et al.Imaging features of pancreatic metastases:a comparison with pancreatic ductal adenocarcinoma [J].Clin Imaging,2018,51:76-82.
参考文献 17
Ren S,Zhang JJ,Chen JY,et al.Evaluation of texture analysis for the differential diagnosis of mass-forming pancreatitis from pancreatic ductal adenocarcinoma on contrast-enhanced CT images[J].Front Oncol,2019,9:1171.
参考文献 18
Beyer G,Habtezion A,Werner J,et al.Chronic pancreatitis [J].Lancet,2020,396(10249):499-512.
参考文献 19
Singh VK,Yadav D,Garg PK.Diagnosis and management of chronic pancreatitis:a review [J].JAMA,2019,322(24):2422-2434.
参考文献 20
Schima W,Böhm G,Rösch CS,et al.Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma:CT and MR imaging for differentiation[J].Cancer Imaging,2020,20(1):52.
参考文献 21
Aslan S,Nural MS,Camlidag I,et al.Efficacy of perfusion CT in differentiating of pancreatic ductal adenocarcinoma from mass-forming chronic pancreatitis and characterization of isoattenuating pancreatic lesions[J].Abdom Radiol(NY),2019,44(2):593-603.
参考文献 22
Frampas E,Morla O,Regenet N,et al.A solid pancreatic mass:tumour or inflammation?[J].Diagn Interv Imaging,2013,94(7/8):741-755.
参考文献 23
王雅杰,崔文静,陈晓,等.增强CT对乏血供胰腺神经内分泌肿瘤及肿块型胰腺炎的鉴别诊断价值 [J].医学研究生学报,2020,33(7):732-736.
目录contents

    摘要

    目的:探讨 CT 增强扫描在肿块型胰腺炎(MFCP)与胰腺导管腺癌(PDAC)鉴别诊断中的价值。方法:选取 2019 年 1 月—2023 年 2 月我院收治的 MFCP 患者 24 例,PDAC 患者 38 例。分析两种病变的临床资料和 CT 表现,包括肿瘤部位、边缘、主胰管扩张、胆管扩张、血管侵犯、囊性坏死、胰腺萎缩、钙化、胰管结石、肿瘤/胰腺强化比等,对两种病变进行鉴别诊断,观察两种病变鉴别诊断的结果。结果:胰腺癌患者平均年龄、黄尿或黄疸患者比例、肝内外胆管扩张、血管侵犯发生率高于慢性肿块型胰腺炎组,腹痛患者比例、胰管结石、胰腺钙化发生率低于肿块型胰腺炎组,差异有统计学意义(P<0.05)。肿块型胰腺炎患者动脉期、门脉期和实质期的肿瘤/胰腺强化比高于对应分期胰腺癌组,差异有统计学意义(P <0.05)。胰腺癌患者动脉期、门静脉期、实质期的肿瘤/胰腺强化比低于平扫期,实质期的肿瘤/胰腺强化高于门脉期,差异有统计学意义(P <0.05)。门脉期肿瘤/胰腺强化比对鉴别肿块型胰腺炎和胰腺癌患者的诊断价值最高,其敏感度、特异度、截断值分别为 87.5%、94.7%、0.825。结论:门脉期肿瘤/胰腺强化比对鉴别肿块型胰腺炎和胰腺癌具有较高诊断价值,当门脉期肿瘤/胰腺强化比小于 0.825 时,需高度警惕胰腺癌。

    Abstract

    Objective To investigate the value of contrast-enhanced computed tomography (CT) features in distinguishing mass-forming pancreatitis (MFCP) from pancreatic ductal adenocarcinoma (PDAC). Methods 24 patients with pathologically confirmed MFCP and 38 patients with PDAC in our hospital from January 2019 to February 2023 were included in this study. Clinical data and CT imaging features, including tumor location, margin, main pancreatic duct dilatation, bile duct dilatation, vascular invasion, cystic necrosis, pancreatic atrophy, calcification, pancreatic duct stone, tumor-to-pancreas enhancement ratio of the two lesions were evaluated. Results Age, the incidence of yellow urine or icterus and bile duct dilatation,vascular invasion in PDAC was higher than MFCP, while abdominal pain, pancreatic duct stone, pancreatic calcification were lower (P<0.05). Tumor-to-pancreas enhancement ratio in MFCP was significantly higher than that in PDAC in arterial phase, portal venous phase and parenchymal phase (P <0.05). Tumor-to-pancreas enhancement ratio in arterial phase, portal venous phase and parenchymal phase was significantly higher than that in plain scan in MFCP (P <0.05). Tumor-to-pancreas enhancement ratio in the portal phase has the highest diagnostic value in differentiating MFCP from PDAC, with sensitivity, specificity and a cut-off value of 87.5%, 94.7% and 0.825, respectively. Conclusion Tumor-to-pancreas enhancement ratio in the portal phase has a high diagnostic value in differentiating MFCP from PDAC. The PDAC should be highly vigilant when the ratio of tumor/ pancreatic enhancement in the portal phase is less than 0.825.

  • 胰腺导管腺癌是胰腺最常见的恶性肿瘤,约占胰腺癌的 90%,五年生存率低于 5%,恶性程度高、预后差,并严重降低患者的生活质量[1]。即使对于少数被诊断为局部可切除肿瘤的患者,术后 5 年存活率不足 20%[2]。肿块型胰腺炎是慢性胰腺炎的一种特殊类型,与自身免疫反应、饮酒和胆道疾病有关,占慢性胰腺炎的 10%~30%[3]。胰腺癌常表现为胰腺局灶性病变,与肿块型胰腺炎具有非常相似的症状、体征和影像学表现。通过影像学检查增强 CT 或 MRI,有时也很难区分胰腺癌和肿块型胰腺炎,延误可切除性胰腺癌的手术时机,或对肿块型胰腺炎选择不必要的手术治疗[4]。研究表明,不同于传统 CT,灌注 CT、双能 CT、MRI 可用于区分胰腺癌和肿块型胰腺炎[5-7],对两种疾病的早期鉴别诊断、治疗方案的选择和疗效评估起着重要作用[8]。肿瘤与胰腺的 CT 增强率为强化各期胰腺病变的 CT 值除以胰腺实质的 CT 值的比值[9]。先前研究已经证实了 CT 增强率在鉴别肿块型胰腺炎和胰腺癌中的价值。然而对于不同期相(动脉期、门脉期和实质期),哪个期相的肿瘤/胰腺强化比对于鉴别两种病变最具有可靠的诊断价值,目前仍无明确定论。本研究旨在探讨肿块型胰腺炎和胰腺癌的 CT 影像特征,以及不同时期肿瘤/胰腺强化比对肿块型胰腺炎和胰腺癌的鉴别诊断价值。

  • 1 资料与方法

  • 1.1 一般资料

  • 收集 2019 年 1 月—2023 年 2 月我院收治的 24 例肿块型胰腺炎患者的资料,均经手术病理证实。纳入标准为:1)所有患者均经手术病理证实为肿块型胰腺炎;2)所有患者均于术前 1 个月内行 CT 平扫及动态增强扫描。排除标准:1)CT 平扫及动态增强扫描资料不全或检查间隔超过 1 个月;2)多灶性肿块型胰腺炎。收集 2019 年—2023 年我院收治的 38 例胰腺癌患者的资料,均经手术病理证实,所有患者在手术前 1 个月内进行了平扫和动态增强 CT 扫描。排除标准:1)平扫和动态增强 CT 资料不完整或检查间隔超过 1 个月;2)肿瘤以囊性为主;3)肿瘤体积过小;4)胰腺具有多发肿瘤。根据 《赫尔辛基原则宣言》保护患者数据。本研究由天津市南开医院伦理委员会批准 ( 审批号: NKYY_YXKT_IRB_01)。

  • 1.2 检查方法

  • 采用 64 层螺旋 CT 扫描仪。在检查前患者禁食 4~6 h,检查前 30 min 口服阴性造影剂(水,600 mL),于仰卧位行腹部常规 CT 平扫;以 3~3.5 mL/s 注射 100 mL 非离子型对比剂进行增强扫描,扫描参数为电压 120 kv,电流 220 mAs,层厚 5 mm,层间距 5 mm。增强扫描采集动脉期(20~25 s)、门脉期(60 s)及实质期(120 s)的图像,最后将数据传至工作站进行图像的后期处理和分析。

  • 1.3 数据处理和图像分析

  • CT 图像由两名具有 10 年以上腹部放射诊断经验的医生独立进行评估,如图像分析中出现分歧,再由更高级别医师参与诊断。主要评估肿瘤的位置、边缘、主胰管扩张、胆管扩张、血管侵犯、囊性坏死、胰腺萎缩、钙化、胰管结石、肿瘤与胰腺的强化比等影像特征。边缘清晰定义为边缘光滑且清晰可见,边缘不清晰定义为肿瘤>1/4 的边缘呈毛刺或浸润样改变。血管癌栓、血管闭塞、狭窄或轮廓畸形提示血管受侵犯。囊性坏死为肿瘤实性部分<50%。平扫期图像用于识别钙化和胰管结石。两位腹部放射科医师对病变及邻近胰腺实质的 CT 衰减(HU)进行 3 次测量,感兴趣区 (ROI)位于肿瘤实性成分内,避开钙化和囊变区。平扫、动脉期、门脉期和实质期的肿瘤/胰腺强化比分别为肿瘤的 CT 值除以胰腺实质的 CT 值。

  • 1.4 统计学分析

  • 数据采用 SPSS 23.0 进行统计分析。计数资料以例(%)表示,比较采用χ2 检验或 Fisher 精确概率法。符合正态分布的计量资料以 x-±s 表示,两组比较采用t检验,多组比较采用方差分析,组间进一步两两比较采用 Bofferoni 检验;不符合正态分布的计量资料以中位数和四分位数间距 [M(P25,P75)]表示,比较采用 Mann-Whitney U 检验。采用受试者工作特征(ROC)曲线分析肿瘤/胰腺强化比与 CA199 鉴别诊断肿块型胰腺炎和胰腺癌的效能。P<0.05 为差异有统计学意义。

  • 2 结果

  • 2.1 肿块型胰腺炎与胰腺癌患者的一般资料比较

  • 腺癌患者平均年龄、CA199 水平高于慢性肿块型胰腺炎组,差异有统计学意义(P <0.05)。胰腺癌组中的腹痛患者比例低于肿块型胰腺炎组,黄尿或黄疸患者比例高于肿块型胰腺炎组,差异有统计学意义 (P <0.05),见表1。

  • 表1 肿块型胰腺炎与胰腺癌患者的一般资料比较

  • 注:a 与胰腺癌组比较,P <0.05

  • 图1 肿块型胰腺炎典型病例的 CT 强化图

  • 图2 胰腺癌典型病例的 CT 强化图

  • 2.2 肿块型胰腺炎和胰腺癌的 CT 征象比较

  • 胰腺癌组的肝内外胆管扩张、血管侵犯发生率高于肿块型胰腺炎组,而胰管结石、胰腺钙化发生率低于肿块型胰腺炎组,差异有统计学意义(P <0.05)。肿块型胰腺炎组动脉期、门脉期和实质期的肿瘤/胰腺强化比高于对应分期胰腺癌组,差异有统计学意义 (P <0.05),见表2。不同强化分期肿块型胰腺炎的肿瘤/胰腺强化比差异无统计学意义。胰腺癌动脉期、门静脉期、实质期的肿瘤/胰腺强化比低于平扫期,实质期的肿瘤/胰腺强化高于门脉期,差异有统计学意义(P <0.05),见表3。

  • 表2 肿块型胰腺炎和胰腺癌的 CT 征象比较

  • 注:a 与胰腺癌组比较,P <0.05

  • 表3 肿块型胰腺炎与胰腺癌的肿瘤 / 胰腺强化比比较

  • 注:a与胰腺癌组比较,P <0.05; b 与平扫期比较,P <0.05;c 与门脉期比较,P <0.05

  • 2.3 CT 征象及 CA199 对鉴别肿块型胰腺炎和胰腺癌的诊断效能

  • 通过绘制 ROC 曲线(图3),分析各影像指标及 CA199 在鉴别肿块型胰腺炎和胰腺癌中的诊断价值,诊断敏感度及特异度见表4。 ROC 曲线分析提示病灶动脉期、门脉期及实质期肿瘤/胰腺强化比均具有较高敏感性与较高特异性。受试者工作曲线(ROC)结果显示门脉期肿瘤/胰腺强化比 AUC 为 0.971,截断值为 0.825,特异度为 94.7%,敏感度为 87.5%。

  • 图3 患者一般资料和 CT 特征的受试者工作特征(ROC)曲线

  • 表4 不同变量在肿块型胰腺炎和胰腺癌的诊断效能

  • 3 讨论

  • 肿块型胰腺炎是一种胰腺炎症疾病,可表现为胰腺的局限性增大[710-11],影像表现上类似胰腺癌,所以误诊的风险很高。研究表明,大约 5%~15%的被诊断为胰腺癌的病例后来被证实为肿块型胰腺炎[10]。肿块型胰腺炎和胰头癌有不同的治疗策略,明确诊断对治疗方法的选择具有重要意义[12-13]。胰头癌如无手术禁忌证,首选根治性胰十二指肠切除术,其可完全切除病变,完整切除胰头和钩突,并进行区域淋巴结清扫,但该术式手术操作难度高,切除范围大,并发症发生率较高,应谨慎选择。而肿块型胰腺炎的手术目的主要是解除胰头肿块产生的压迫症状,不需对淋巴结进行廓清,因此首选术后并发症少,且对机体创伤小的术式,如保留十二指肠的胰头切除术等。因此,在术前对病变做出正确诊断,选择合适的手术方式,对患者的治疗和预后具有重要意义。

  • CA199 可作为鉴别肿块型胰腺炎和胰腺癌的血清标志物,在本研究中,胰腺癌患者 CA199 值高于慢性肿块型胰腺炎组,CA199 是一种黏蛋白,存在于胰腺、胆管、胃和肠上皮细胞中。胰腺癌细胞生长、侵袭和损伤正常的胰腺和胆管细胞,会导致 CA199 的释放,同时胰腺癌细胞在自身生长过程也可以释放 CA199。但 CA199 的假阴性率较高[31014], CA199 不升高时,影像所见的胰头肿块也不能排除胰腺癌诊断,本研究中 8 例 CA199 升高是肿块型胰腺炎,4 例不升高是胰腺癌。另一方面,CA199 升高会怀疑胰腺癌,但只有在影像学检查 CT 或 MRI 扫描时发现胰腺有可疑肿块时,其升高才有意义。

  • 本研究中,胰腺癌患者平均年龄高于慢性肿块型胰腺炎组,表明随着年龄的增长,患胰腺癌的风险呈逐渐增长的趋势。胰腺癌患者黄尿或黄疸、肝内外胆管扩张、血管侵犯比例高于慢性肿块型胰腺炎组,胰腺癌发展过程中病灶会压迫或浸润胆管,进而引起梗阻性黄疸或黄尿以及肝内外胆管扩张。胰腺癌中发生于胰头者多见,胰头癌容易引起黄疸,因为胰头的位置是胆总管下端汇入十二指肠的位置,胆总管下端与胰管在该位置汇合,会逐步汇合为壶腹部,最终到达十二指肠。大部分胰头癌会压迫胆管,引起胆管狭窄,造成胆汁无法流出,从而导致黄尿或黄疸、肝内外胆管扩张的出现[15-16]。肿块型胰腺炎患者胆总管扩张程度轻、末端逐渐变细、肝内胆管多无扩张。胰腺癌是一种恶性程度较高的消化道恶性肿瘤,其生长速度快、浸润性强,易通过血液、淋巴系统等方式转移至远处器官。

  • 在本研究中,慢性肿块型胰腺炎患者腹痛发生率高于胰腺癌组。腹痛的原因主要是因为胰腺水肿、炎性渗出液和胰液外溢刺激腹膜和腹膜后组织,从而引起腹痛。Ren 等[17]研究显示肿块型胰腺炎和胰腺癌在胰管扩张方面没有显著差异,与本研究结果一致。本研究中慢性肿块型胰腺炎患者胰管结石、胰腺钙化比例高于胰腺癌组,其原因可能是在炎性病变中,反复和进行性炎性纤维化引起,可不同程度地损害内分泌和外分泌功能,导致钙沉积[18],这些都会导致胰管结石的形成[19]。胰腺癌通常与一些影像特征有关,包括上游胰管和/或肝内外胆管扩张,胰腺实质萎缩,以及肠系膜/脾血管受累。

  • 既往研究已经介绍了几种方法来区分肿块型胰腺炎和胰腺癌,包括灌注 CT 和灌注参数值在鉴别诊断中的意义,但相对比较大的辐射剂量限制了灌注 CT 的使用范围[5920]。Ren 等[9]研究发现,延迟对比增强是区分慢性肿块型胰腺炎组和胰腺癌的重要预测指标,其临界值为 70.5 HU,敏感度和特异度分别为 84.2%和 84.7%,并证实了 CT 增强率在鉴别肿块型胰腺炎和胰腺癌中的价值。本研究发现肿块型胰腺炎组的动脉期、门脉期和实质期的肿瘤/胰腺强化比高于胰腺癌组。与 Ren 等[9]和 Aslan 等[21]研究不同,本研究发现门静脉期肿瘤/胰腺强化比是鉴别两种病变 CT 影像特征的重要预测指标,其敏感性为 87.5%,特异性为 94.7%。其原因可能为肿块型胰腺炎中血管扩张充血,通透性增加,局部血流量增多,且肿块型胰腺炎虽有纤维间质,但其纤维间质较为疏松,对比剂进入相对较快、较多,因而其在门脉期 CT 值更高[22-23]。胰腺癌具有明显的间质纤维化,为乏血供肿块,在门脉期肿瘤和胰腺之间具有最佳对比度。因此门脉期肿瘤/胰腺强化比可提高增强 CT 对肿块型胰腺炎和胰腺癌的鉴别诊断效率。

  • 本研究证实患者年龄、肝内外胆管扩张、胰管结石、钙化和 CA199、门脉期肿瘤/胰腺强化比在鉴别肿块型胰腺炎和胰腺癌中具有重要作用。其可增加临床对于肿块型胰腺炎和胰腺癌的鉴别方法,减少误诊,为临床制定治疗方案提供有力的数据资料和影像依据。临床中对于怀疑胰腺癌患者应首选 CT 增强扫描提高诊断率,并结合患者的症状和临床表现等减少误诊、漏诊。同时对于有恶变风险的肿块型胰腺炎,可采用肿瘤标志物结合该方法进行随诊,监测病情变化,提早预警。本研究存在一定不足,因样本量较小,容易出现统计学误差,后续可开展大样本、多中心研究。

  • 本研究证实患者年龄、腹痛、肝内外胆管扩张、胰管结石、钙化、血管侵犯和 CA199、门脉期肿瘤/胰腺强化比在鉴别肿块型胰腺炎和胰腺癌中具有重要作用。其可增加临床对于肿块型胰腺炎和胰腺癌的鉴别方法,减少误诊,为临床制定治疗方案提供有力的数据资料和影像依据。临床中对于怀疑胰腺癌患者应首选 CT 增强扫描提高诊断率,并结合患者的症状和临床表现等减少误诊、漏诊。同时对于有恶变风险的肿块型胰腺炎,可采用肿瘤标志物结合该方法进行随诊,监测病情变化,提早预警。本研究存在一定不足,因样本量较小,容易出现统计学误差,后续可开展大样本、多中心研究。

  • 参考文献

    • [1] Franck C,MÜller C,Rosania R,et al.Advanced pancreatic ductal adenocarcinoma:moving forward[J].Cancers,2020,12(7):1955.

    • [2] Mizrahi JD,Surana R,Valle JW,et al.Pancreatic cancer [J].Lancet,2020,395(10242):2008-2020.

    • [3] Gu XJ,Liu R.Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly[J].Clin Interv Aging,2016,11:1365-1370.

    • [4] Balthazar EJ.Pancreatitis associated with pancreatic carcinoma.Preoperative diagnosis:role of CT imaging in detection and evaluation[J].Pancreatology,2005,5(4/5):330-344.

    • [5] Ruan ZB,Jiao J,Min DY,et al.Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head [J].Oncol Lett,2018,15(6):9735-9744.

    • [6] Yadav AK,Sharma R,Kandasamy D,et al.Perfusion CT-Can it resolve the pancreatic carcinoma versus mass forming chronic pancreatitis conundrum?[J].Pancreatology,2016,16(6):979-987.

    • [7] Yin QH,Zou XN,Zai XD,et al.Pancreatic ductal adenocarcinoma and chronic mass-forming pancreatitis:differentiation with dual-energy MDCT in spectral imaging mode[J].Eur J Radiol,2015,84(12):2470-2476.

    • [8] Lu N,Feng XY,Hao SJ,et al.64-slice CT perfusion imaging of pancreatic adenocarcinoma and mass-forming chronic pancreatitis [J].Acad Radiol,2011,18(1):81-88.

    • [9] Ren S,Chen X,Cui WJ,et al.Differentiation of chronic massforming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography [J].Cancer Manag Res,2019,11:7857-7866.

    • [10] Elsherif SB,Virarkar M,Javadi S,et al.Pancreatitis and PDAC:association and differentiation[J].Abdom Radiol(NY),2020,45(5):1324-1337.

    • [11] Deng Y,Ming B,Zhou T,et al.Radiomics model based on MR images to discriminate pancreatic ductal adenocarcinoma and mass-forming chronic pancreatitis lesions [J].Front Oncol,2021,11:620981.

    • [12] 陈祺,李东恩,姜建帅.195 例早期胰腺癌手术方式与生存率的关系[J].中国中西医结合外科杂志,2016,22(1):3-5.

    • [13] 张太平,李建,赵玉沛.胰头部肿块型慢性胰腺炎的处理对策 [J].中华消化外科杂志,2014,13(4):244-246.

    • [14] Azizian A,RÜhlmann F,Krause T,et al.CA19-9 for detecting recurrence of pancreatic cancer[J].Sci Rep,2020,10(1):1332.

    • [15] Beker K,Lee KS,Tsai LL,et al.Differentiation of pancreatic head ductal adenocarcinoma from inflammatory pancreatic pseudomass by MR cholangio-pancreatography:utility of the duct-interrupted,corona,and attraction signs[J].Abdom Radiol(NY),2019,44(12):4048-4056.

    • [16] Galia M,Albano D,Picone D,et al.Imaging features of pancreatic metastases:a comparison with pancreatic ductal adenocarcinoma [J].Clin Imaging,2018,51:76-82.

    • [17] Ren S,Zhang JJ,Chen JY,et al.Evaluation of texture analysis for the differential diagnosis of mass-forming pancreatitis from pancreatic ductal adenocarcinoma on contrast-enhanced CT images[J].Front Oncol,2019,9:1171.

    • [18] Beyer G,Habtezion A,Werner J,et al.Chronic pancreatitis [J].Lancet,2020,396(10249):499-512.

    • [19] Singh VK,Yadav D,Garg PK.Diagnosis and management of chronic pancreatitis:a review [J].JAMA,2019,322(24):2422-2434.

    • [20] Schima W,Böhm G,Rösch CS,et al.Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma:CT and MR imaging for differentiation[J].Cancer Imaging,2020,20(1):52.

    • [21] Aslan S,Nural MS,Camlidag I,et al.Efficacy of perfusion CT in differentiating of pancreatic ductal adenocarcinoma from mass-forming chronic pancreatitis and characterization of isoattenuating pancreatic lesions[J].Abdom Radiol(NY),2019,44(2):593-603.

    • [22] Frampas E,Morla O,Regenet N,et al.A solid pancreatic mass:tumour or inflammation?[J].Diagn Interv Imaging,2013,94(7/8):741-755.

    • [23] 王雅杰,崔文静,陈晓,等.增强CT对乏血供胰腺神经内分泌肿瘤及肿块型胰腺炎的鉴别诊断价值 [J].医学研究生学报,2020,33(7):732-736.

图1 肿块型胰腺炎典型病例的 CT 强化图

图2 胰腺癌典型病例的 CT 强化图

图3 患者一般资料和 CT 特征的受试者工作特征(ROC)曲线

表1 肿块型胰腺炎与胰腺癌患者的一般资料比较

表2 肿块型胰腺炎和胰腺癌的 CT 征象比较

表3 肿块型胰腺炎与胰腺癌的肿瘤 / 胰腺强化比比较

表4 不同变量在肿块型胰腺炎和胰腺癌的诊断效能

图表 1/1

  • 参考文献

    • [1] Franck C,MÜller C,Rosania R,et al.Advanced pancreatic ductal adenocarcinoma:moving forward[J].Cancers,2020,12(7):1955.

    • [2] Mizrahi JD,Surana R,Valle JW,et al.Pancreatic cancer [J].Lancet,2020,395(10242):2008-2020.

    • [3] Gu XJ,Liu R.Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly[J].Clin Interv Aging,2016,11:1365-1370.

    • [4] Balthazar EJ.Pancreatitis associated with pancreatic carcinoma.Preoperative diagnosis:role of CT imaging in detection and evaluation[J].Pancreatology,2005,5(4/5):330-344.

    • [5] Ruan ZB,Jiao J,Min DY,et al.Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head [J].Oncol Lett,2018,15(6):9735-9744.

    • [6] Yadav AK,Sharma R,Kandasamy D,et al.Perfusion CT-Can it resolve the pancreatic carcinoma versus mass forming chronic pancreatitis conundrum?[J].Pancreatology,2016,16(6):979-987.

    • [7] Yin QH,Zou XN,Zai XD,et al.Pancreatic ductal adenocarcinoma and chronic mass-forming pancreatitis:differentiation with dual-energy MDCT in spectral imaging mode[J].Eur J Radiol,2015,84(12):2470-2476.

    • [8] Lu N,Feng XY,Hao SJ,et al.64-slice CT perfusion imaging of pancreatic adenocarcinoma and mass-forming chronic pancreatitis [J].Acad Radiol,2011,18(1):81-88.

    • [9] Ren S,Chen X,Cui WJ,et al.Differentiation of chronic massforming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography [J].Cancer Manag Res,2019,11:7857-7866.

    • [10] Elsherif SB,Virarkar M,Javadi S,et al.Pancreatitis and PDAC:association and differentiation[J].Abdom Radiol(NY),2020,45(5):1324-1337.

    • [11] Deng Y,Ming B,Zhou T,et al.Radiomics model based on MR images to discriminate pancreatic ductal adenocarcinoma and mass-forming chronic pancreatitis lesions [J].Front Oncol,2021,11:620981.

    • [12] 陈祺,李东恩,姜建帅.195 例早期胰腺癌手术方式与生存率的关系[J].中国中西医结合外科杂志,2016,22(1):3-5.

    • [13] 张太平,李建,赵玉沛.胰头部肿块型慢性胰腺炎的处理对策 [J].中华消化外科杂志,2014,13(4):244-246.

    • [14] Azizian A,RÜhlmann F,Krause T,et al.CA19-9 for detecting recurrence of pancreatic cancer[J].Sci Rep,2020,10(1):1332.

    • [15] Beker K,Lee KS,Tsai LL,et al.Differentiation of pancreatic head ductal adenocarcinoma from inflammatory pancreatic pseudomass by MR cholangio-pancreatography:utility of the duct-interrupted,corona,and attraction signs[J].Abdom Radiol(NY),2019,44(12):4048-4056.

    • [16] Galia M,Albano D,Picone D,et al.Imaging features of pancreatic metastases:a comparison with pancreatic ductal adenocarcinoma [J].Clin Imaging,2018,51:76-82.

    • [17] Ren S,Zhang JJ,Chen JY,et al.Evaluation of texture analysis for the differential diagnosis of mass-forming pancreatitis from pancreatic ductal adenocarcinoma on contrast-enhanced CT images[J].Front Oncol,2019,9:1171.

    • [18] Beyer G,Habtezion A,Werner J,et al.Chronic pancreatitis [J].Lancet,2020,396(10249):499-512.

    • [19] Singh VK,Yadav D,Garg PK.Diagnosis and management of chronic pancreatitis:a review [J].JAMA,2019,322(24):2422-2434.

    • [20] Schima W,Böhm G,Rösch CS,et al.Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma:CT and MR imaging for differentiation[J].Cancer Imaging,2020,20(1):52.

    • [21] Aslan S,Nural MS,Camlidag I,et al.Efficacy of perfusion CT in differentiating of pancreatic ductal adenocarcinoma from mass-forming chronic pancreatitis and characterization of isoattenuating pancreatic lesions[J].Abdom Radiol(NY),2019,44(2):593-603.

    • [22] Frampas E,Morla O,Regenet N,et al.A solid pancreatic mass:tumour or inflammation?[J].Diagn Interv Imaging,2013,94(7/8):741-755.

    • [23] 王雅杰,崔文静,陈晓,等.增强CT对乏血供胰腺神经内分泌肿瘤及肿块型胰腺炎的鉴别诊断价值 [J].医学研究生学报,2020,33(7):732-736.

  • 用微信扫一扫

    用微信扫一扫